Be part of the knowledge.™

Global Neurology Academy

The Global Neurology Academy (GNA) Series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.

For more information about GNA, visit www.globalneurologyacademy.org.

38

LikeLikedUnlike

1-15 of 60

CME/CE In-Person & Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
1.00 credits
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
CME/CE Virtual Event
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
October 07, 2026
06:00 PM - 07:00 PM CEST
1.00 credits
An Exclusive Peer Dinner with Gil I. Wolfe MD, FAAN, Discussing Advancing Treat-to-Target Care in Generalized Myasthenia Gravis
CME/CE In-Person Event
An Exclusive Peer Dinner with Gil I. Wolfe MD, FAAN, Discussing Advancing Treat-to-Target Care in Generalized Myasthenia Gravis
October 10, 2026
New York, New York
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 22, 2026
Austin, Texas
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 23, 2026
Houston, Texas
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 24, 2026
Atlanta, Georgia
1.50 credits
advertisement
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
November 05, 2026
Phoenix, Arizona
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
November 07, 2026
Miami, Florida
1.50 credits
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
CME/CE Broadcast Replay
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
- Dani Cabral, MD
- David Weisman, MD
1.00 credits
Stroke-Like Symptoms During Treatment: Safety First
MinuteCE®
Stroke-Like Symptoms During Treatment: Safety First
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
MinuteCE®
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
- Dani Cabral, MD
- David Weisman, MD
0.50 credits 6 episodes
Talking Through Benefits, Risks, and Patient Priorities
MinuteCE®
Talking Through Benefits, Risks, and Patient Priorities
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
advertisement
Antithrombotics and Amyloid Therapy: Balancing Risk
MinuteCE®
Antithrombotics and Amyloid Therapy: Balancing Risk
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Who Is Ready for Amyloid-Targeting Therapy?
MinuteCE®
Who Is Ready for Amyloid-Targeting Therapy?
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Borderline Biomarkers: When a Blood Test Is Not Enough
MinuteCE®
Borderline Biomarkers: When a Blood Test Is Not Enough
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended